Literature DB >> 24578219

Dietary phosphorus restriction by a standard low-protein diet decreased serum fibroblast growth factor 23 levels in patients with early and advanced stage chronic kidney disease.

Shunsuke Goto1, Kentaro Nakai, Keiji Kono, Yuriko Yonekura, Jun Ito, Hideki Fujii, Shinichi Nishi.   

Abstract

BACKGROUND: Elevated serum fibroblast growth factor 23 (FGF23) levels are associated with mortality, cardiovascular disease, and disease progression in patients with chronic kidney disease (CKD). Although recent studies demonstrated that FGF23 levels decreased in response to dietary restriction of phosphorus and/or use of phosphate binders, research on the effects of a standard low-protein diet is lacking.
METHODS: The effects of a standard low-protein diet on serum FGF23, intact parathyroid hormone, and 1,25-dihydroxyvitamin D levels were investigated in patients with early (n = 15) and advanced (n = 20) CKD.
RESULTS: Serum FGF23 levels decreased in both groups. Changes in FGF23 levels correlated with changes in 24 h urinary phosphorus excretion in the advanced CKD group. Decreased serum intact parathyroid hormone levels were observed only in the advanced CKD group and increased serum 1,25-dihydroxyvitamin D levels only in the early CKD group.
CONCLUSIONS: These findings suggest that consuming standard low-protein diet decreased serum FGF23 levels in patients with CKD. Serum FGF23 levels may therefore be a useful marker to monitor the effects of a low-protein diet in early and advanced stage CKD.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24578219     DOI: 10.1007/s10157-014-0947-4

Source DB:  PubMed          Journal:  Clin Exp Nephrol        ISSN: 1342-1751            Impact factor:   2.801


  36 in total

1.  Fibroblast growth factor-23 relationship to dietary phosphate and renal phosphate handling in healthy young men.

Authors:  Serge L Ferrari; Jean-Philippe Bonjour; René Rizzoli
Journal:  J Clin Endocrinol Metab       Date:  2004-12-21       Impact factor: 5.958

2.  Acute effect of oral phosphate loading on serum fibroblast growth factor 23 levels in healthy men.

Authors:  Y Nishida; Y Taketani; H Yamanaka-Okumura; F Imamura; A Taniguchi; T Sato; E Shuto; K Nashiki; H Arai; H Yamamoto; E Takeda
Journal:  Kidney Int       Date:  2006-10-25       Impact factor: 10.612

3.  Fibroblast growth factor 23 is a counter-regulatory phosphaturic hormone for vitamin D.

Authors:  Shiguang Liu; Wen Tang; Jianping Zhou; Jason R Stubbs; Qiang Luo; Min Pi; L Darryl Quarles
Journal:  J Am Soc Nephrol       Date:  2006-04-05       Impact factor: 10.121

4.  Circulating FGF-23 is regulated by 1alpha,25-dihydroxyvitamin D3 and phosphorus in vivo.

Authors:  Hitoshi Saito; Akira Maeda; Shu-Ichi Ohtomo; Michinori Hirata; Kenichiro Kusano; Shigeaki Kato; Etsuro Ogata; Hiroko Segawa; Ken-Ichi Miyamoto; Naoshi Fukushima
Journal:  J Biol Chem       Date:  2004-11-05       Impact factor: 5.157

5.  Regulation of C-terminal and intact FGF-23 by dietary phosphate in men and women.

Authors:  Sherri -Ann M Burnett; Samantha C Gunawardene; F Richard Bringhurst; Harald Jüppner; Hang Lee; Joel S Finkelstein
Journal:  J Bone Miner Res       Date:  2006-08       Impact factor: 6.741

6.  Sevelamer hydrochloride and calcium bicarbonate reduce serum fibroblast growth factor 23 levels in dialysis patients.

Authors:  Fumihiko Koiwa; Junichiro J Kazama; Akihide Tokumoto; Noritaka Onoda; Hitoshi Kato; Tomoyuki Okada; Tomoko Nii-Kono; Masafumi Fukagawa; Takashi Shigematsu
Journal:  Ther Apher Dial       Date:  2005-08       Impact factor: 1.762

7.  Possible involvement of circulating fibroblast growth factor 23 in the development of secondary hyperparathyroidism associated with renal insufficiency.

Authors:  Takashi Shigematsu; Junichiro James Kazama; Takeyoshi Yamashita; Seiji Fukumoto; Tatsuo Hosoya; Fumitake Gejyo; Masafumi Fukagawa
Journal:  Am J Kidney Dis       Date:  2004-08       Impact factor: 8.860

8.  High levels of serum fibroblast growth factor (FGF)-23 are associated with increased mortality in long haemodialysis patients.

Authors:  Guillaume Jean; Jean-Claude Terrat; Thierry Vanel; Jean-Marc Hurot; Christie Lorriaux; Brice Mayor; Charles Chazot
Journal:  Nephrol Dial Transplant       Date:  2009-04-25       Impact factor: 5.992

9.  Revised equations for estimated GFR from serum creatinine in Japan.

Authors:  Seiichi Matsuo; Enyu Imai; Masaru Horio; Yoshinari Yasuda; Kimio Tomita; Kosaku Nitta; Kunihiro Yamagata; Yasuhiko Tomino; Hitoshi Yokoyama; Akira Hishida
Journal:  Am J Kidney Dis       Date:  2009-04-01       Impact factor: 8.860

10.  Fibroblast growth factor 23 and left ventricular hypertrophy in chronic kidney disease.

Authors:  Orlando M Gutiérrez; James L Januzzi; Tamara Isakova; Karen Laliberte; Kelsey Smith; Gina Collerone; Ammar Sarwar; Udo Hoffmann; Erin Coglianese; Robert Christenson; Thomas J Wang; Christopher deFilippi; Myles Wolf
Journal:  Circulation       Date:  2009-05-04       Impact factor: 29.690

View more
  12 in total

Review 1.  The FGF23 and Klotho system beyond mineral metabolism.

Authors:  Makoto Kuro-O
Journal:  Clin Exp Nephrol       Date:  2016-11-12       Impact factor: 2.801

Review 2.  [FGF23 and the heart].

Authors:  I Ezumba; L D Quarles; C P Kovesdy
Journal:  G Ital Nefrol       Date:  2014 Nov-Dec

Review 3.  Dietary Protein Intake and Bone Across Stages of Chronic Kidney Disease.

Authors:  Elizabeth R Stremke; Annabel Biruete; Kathleen M Hill Gallant
Journal:  Curr Osteoporos Rep       Date:  2020-06       Impact factor: 5.096

Review 4.  Klotho/FGF23 Axis in Chronic Kidney Disease and Cardiovascular Disease.

Authors:  Xiang Lu; Ming Chang Hu
Journal:  Kidney Dis (Basel)       Date:  2016-11-17

Review 5.  Is Fibroblast growth factor 23 the leading cause of increased mortality among chronic kidney disease patients? A narrative review.

Authors:  Usama A Sharaf El Din; Mona M Salem; Dina O Abdulazim
Journal:  J Adv Res       Date:  2017-02-27       Impact factor: 10.479

Review 6.  Fibroblast growth factor 23: are we ready to use it in clinical practice?

Authors:  Annet Bouma-de Krijger; Marc G Vervloet
Journal:  J Nephrol       Date:  2020-03-04       Impact factor: 3.902

Review 7.  New Aspects of the Kidney in the Regulation of Fibroblast Growth Factor 23 (FGF23) and Mineral Homeostasis.

Authors:  Maria L Mace; Klaus Olgaard; Ewa Lewin
Journal:  Int J Mol Sci       Date:  2020-11-20       Impact factor: 5.923

8.  Serum FGF23 levels may not be associated with serum phosphate and 1,25-dihydroxyvitamin D levels in patients with Fanconi syndrome-induced hypophosphatemia.

Authors:  Shunsuke Goto; Hideki Fujii; Keiji Kono; Kentaro Watanabe; Kentaro Nakai; Shinichi Nishi
Journal:  Clin Kidney J       Date:  2016-09-09

Review 9.  Fibroblast Growth Factor 23 and Adverse Clinical Outcomes in Type 2 Diabetes: a Bitter-Sweet Symphony.

Authors:  Stanley M H Yeung; Stephan J L Bakker; Gozewijn D Laverman; Martin H De Borst
Journal:  Curr Diab Rep       Date:  2020-08-28       Impact factor: 4.810

Review 10.  The Influence of Dietary Interventions on Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD).

Authors:  Jacek Rysz; Beata Franczyk; Robert Rokicki; Anna Gluba-Brzózka
Journal:  Nutrients       Date:  2021-06-16       Impact factor: 5.717

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.